IL17A and psoriasis: ,49 While head-to-head trials have shown dual blockade of IL-17A and IL-17F to be superior to biologic targeting IL-17A, IL-12/23, TNF-α in patients with psoriasis, further data is required to confirm whether this finding replicated in patients with PsA.50